Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study (2017)
- Authors:
- Autor USP: PEREIRA, JULIANA - FM
- Unidade: FM
- DOI: 10.3324/haematol.2016.152496
- Subjects: LINFOMA; PROGNÓSTICO; SOBREVIVÊNCIA LIVRE DE DOENÇA; ANTINEOPLÁSICOS
- Language: Inglês
- Imprenta:
- Source:
- Título: Haematologica
- ISSN: 0390-6078
- Volume/Número/Paginação/Ano: v. 102, n. 5, p. 895-902, 2017
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by-nc
-
ABNT
VERHOEF, Gregor et al. Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study. Haematologica, v. 102, n. 5, p. 895-902, 2017Tradução . . Disponível em: https://doi.org/10.3324/haematol.2016.152496. Acesso em: 12 jan. 2026. -
APA
Verhoef, G., Robak, T., Huang, H., Pylypenko, H., Siritanaratkul, N., Pereira, J., et al. (2017). Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study. Haematologica, 102( 5), 895-902. doi:10.3324/haematol.2016.152496 -
NLM
Verhoef G, Robak T, Huang H, Pylypenko H, Siritanaratkul N, Pereira J, Drach J, Mayer J, Okamoto R, Pei L, Rooney B, Cakana A, Velde H van de, Cavalli F. Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study [Internet]. Haematologica. 2017 ; 102( 5): 895-902.[citado 2026 jan. 12 ] Available from: https://doi.org/10.3324/haematol.2016.152496 -
Vancouver
Verhoef G, Robak T, Huang H, Pylypenko H, Siritanaratkul N, Pereira J, Drach J, Mayer J, Okamoto R, Pei L, Rooney B, Cakana A, Velde H van de, Cavalli F. Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study [Internet]. Haematologica. 2017 ; 102( 5): 895-902.[citado 2026 jan. 12 ] Available from: https://doi.org/10.3324/haematol.2016.152496 - A difficult case of angioimmunoblastic T-cell lymphoma to diagnose
- Clinical prognostic models in diffuse large B cell lymphoma patients are still essencial in the rituximab era
- Effects of glucocorticoids on interstitial glucose concentrations in individuals with hematologic cancer and without known diagnosis of diabetes: a pilot study
- CD4+ lymphocytes in asymptomatic HTLV-1 carriers present cell cycle arrest in GO/G1 phase
- Follicular lymphoma: refining prognostic models and impact of pod-24 in clinical outcomes
- Estudo de células precuroras em leucemias agudas: identificação e fator de prognóstico das proteínas Bcl-2, Bax e CD95/Fas/APO-1
- Panoramic and skull imaging may aid in the identification of multiple myeloma lesions
- Radiographic patterns of multiple myeloma in the jawbones of patients treated with intravenous bisphosphonates
- Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclosphosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM 3002 study
- Adult T-Cell Leukemia/Lymphoma: A Clinical and Epidemiological Analysis at the Medicine School of Sao Paulo University
Informações sobre o DOI: 10.3324/haematol.2016.152496 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
